Edition:
United States

SymBio Pharmaceuticals Ltd (4582.T)

4582.T on Tokyo Stock Exchange

238JPY
21 Sep 2017
Change (% chg)

¥4 (+1.71%)
Prev Close
¥234
Open
¥240
Day's High
¥244
Day's Low
¥235
Volume
2,004,400
Avg. Vol
2,776,890
52-wk High
¥396
52-wk Low
¥196

Latest Key Developments (Source: Significant Developments)

Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl
Wednesday, 20 Sep 2017 06:50am EDT 

Sept 20 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited.$12.5 million upfront payment plus future potential milestones and royalty payments are part of deal​.Symbio has estimated that sales of Treakisym are estimated to grow to $90 million in 2018​.Company will also receive royalties on future net sales of licensed Bendamustine products.Symbio will target for approval of a product in 2020​.  Full Article

SymBio Pharmaceuticals commences phase III clinical trial for TREAKISYM
Thursday, 31 Aug 2017 03:03am EDT 

Aug 31(Reuters) - SymBio Pharmaceuticals Ltd <4582.T>:Says it initiated a phase 3 study of the anticancer drug TREAKISYM® for the indication of relapsed/refractory diffuse large B-cell lymphoma .  Full Article

SymBio Pharmaceuticals says approval in Japan of anti-cancer drug TREAKISYM® intravenous infusion 25 mg
Wednesday, 28 Sep 2016 02:30am EDT 

SymBio Pharmaceuticals Ltd <4582.T>:Says TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product of the anti-cancer drug TREAKISYM® is approved for manufacturing and marketing in Japan.  Full Article

SymBio Pharmaceuticals says initiation of phase 3 clinical trial on SyB P-1501
Monday, 13 Jun 2016 02:35am EDT 

SymBio Pharmaceuticals Ltd <4582.T> :Announces the Phase 3 clinical trial on “SyB P-1501” – a drug for patient-controlled short-term management of acute postoperative pain during hospitalization, was initiated in Japan.  Full Article

SymBio Pharmaceuticals announces shareholding structure change
Thursday, 19 May 2016 05:06am EDT 

SymBio Pharmaceuticals Ltd <4582.T> : Says a Tokyo-based investment business limited partnership ups stake to 11.56 percent from 0 percent and becomes the top shareholder of the company .Says change occurs on May 11.  Full Article

SymBio announces incorporation of its U.S. subsidiary
Tuesday, 10 May 2016 09:10pm EDT 

SymBio Pharmaceuticals Ltd <4582.T>: Says the company has incorporated its wholly-owned subsidiary in U.S.- SymBio Pharma USA, Inc. on May 11 .Says SymBio Pharma USA, Inc. is engaged in research and development, manufacturing and sales of pharmaceutical products.  Full Article

Symbio Pharmaceuticals issues third series unsecured convertible bonds with warrants via private placement
Thursday, 21 Apr 2016 08:15pm EDT 

Symbio Pharmaceuticals Ltd:Issues the third series unsecured convertible bonds with warrants via private placement and raises 3 billion yen on April 22.  Full Article

Symbio Pharmaceuticals to issue third series unsecured convertible bonds with warrants through private placement
Wednesday, 6 Apr 2016 03:00am EDT 

Symbio Pharmaceuticals Ltd:To issue the third series unsecured convertible bonds with warrants through private placement to Japan-based investment limited liability partnership.To raise 3 billion yen.Says payment date April 22.Conversion price of 211 yen.Proceeds raised will be used for research and development.  Full Article

Symbio Pharmaceuticals and Teikyo Heisei University enter into a Joint Research and Development Agreement
Sunday, 7 Feb 2016 06:00pm EST 

Symbio Pharmaceuticals Ltd:Says the co and Teikyo Heisei University enters into an agreement on Feb. 8 with Teikyo Heisei University to collaborate on the research and development of an innovative anti-cancer drug which uses the TTR1 nano-agonist molecule.  Full Article

Symbio Pharmaceuticals starts Global Phase 3 Trial for IV Rigosertib
Sunday, 27 Dec 2015 06:00pm EST 

Symbio Pharmaceuticals Ltd:Says it has started the global Phase 3 trial in Japan for the IV formulation of rigosertib to treat relapsed or refractory higher-risk myelodysplastic syndromes (HR-MDS) patients.While SymBio will conduct the INSPIRE trial in Japan, SymBio’s U.S. partner, Onconova Therapeutics, Inc will conduct the INSPIRE trial in the U.S and Europe.  Full Article

BRIEF-Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl

* Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited